Sone-191 -

• SONE-191 preclinical study
• SONE-191 clinical trial
• SONE-191 antifibrotic mechanism

• In vitro: Reduced cytokine release from stimulated immune cells; inhibited markers of myofibroblast differentiation in cultured fibroblasts.
• In vivo (animal models): Attenuation of inflammation and fibrosis in models such as bleomycin-induced pulmonary fibrosis or chemically induced liver fibrosis (reported endpoints include histology, hydroxyproline content, and inflammatory cell infiltration).
• Safety/toxicology: Standard GLP toxicology studies reportedly performed; tolerability in animals at pharmacologically active doses, though thorough safety profile and human-relevant toxicity remain to be established.

Industry traction: Voltora Motors announced a partnership to integrate SONE‑191 into its upcoming V‑X2 crossover, targeting a 2027 launch. Early simulations suggest a 30 % increase in total vehicle range for the same footprint.